TWILIGHT Study
Research type
Research Study
Full title
TWILIGHT Study: Ticagrelor with Aspirin or alone in high-risk patients after coronary intervention.
IRAS ID
195312
Contact name
Vijay Kunadian
Contact email
Sponsor organisation
Mount Sinai
Eudract number
2014-005498-35
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
This is a multi-centre, global research study comparing the use of ticagrelor and aspirin as Dual Antiplatelet Therapy (DAPT) to ticagrelor alone (antiplatelet monotherapy) to treat high-risk patients that have received percutaneous coronary intervention (PCI) with at least one drug-eluting stent (DES).
A PCI is a procedure done through the skin using a catheter (a thin flexible tube) to insert a small structure called a stent to open up a blocked blood vessel in the heart. This helps improve blood flow and reduces heart-related chest pain (angina). A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly release a drug to control the rate of tissue growth and prevent scars from forming. A patient is considered high-risk if they meet certain clinical criteria.
TWILIGHT will analyse how high-risk patients respond to ticagrelor with aspirin in comparison to ticagrelor alone following a PCI and whether this can reduce clinically relevant bleeding and major ischemic events (when there is not enough blood being supplied to a major organ such as the heart).
REC name
South Central - Oxford A Research Ethics Committee
REC reference
16/SC/0159
Date of REC Opinion
10 May 2016
REC opinion
Further Information Favourable Opinion